Snap Bio Inc., of San Diego, along with Biomedical Research of Barcelona, said its lead candidate, SNP-162, overcame disabling drug-resistance in treating recurrent advanced and metastatic liver cancer. SNP-162 is designed to inhibit the growth of liver cancer cell lines that are resistant to Sorafenib, which is FDA-approved for treating inoperable hepatocellular carcinoma.